NCT02414594View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Elevated Lipoprotein(a)
Interventions
DRUG

IONIS-APO(a)-LRx

Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection

DRUG

Sterile Normal Saline (0.9% NaCl)

Calculated volume to match active comparator

Trial Locations (1)

M9L 3A2

Clinical Site, Toronto

Sponsors

Collaborators (1)

Akcea Therapeutics
All Listed Sponsors
collaborator

Akcea Therapeutics

INDUSTRY

lead

Ionis Pharmaceuticals, Inc.

INDUSTRY